Treatment Advances for Metastatic Breast Cancer Tied to Decrease in Deaths - Cancer Therapy Advisor

Among patients with ER+/HER2+ breast cancer, the median survival after distant recurrence increased from 2.3 years in 2000 to 4.8 years in 2019.

Recent advances in the treatment of metastatic breast cancer have improved population-level survival, according to research presented at the 2022 ASCO Annual Meeting.  Researchers conducted a modeli… [+3443 chars]

full article...